Vascepa is a brand name for the generic drug icosapent ethyl, which is used to lower triglyceride levels in the blood. According to DrugPatentWatch [1], Vascepa's patent expired in 2020, allowing other companies to produce generic versions of the drug. However, as of now, there are no FDA-approved generic versions of Vascepa available on the market.

In terms of effectiveness, a comparison between Vascepa and Lovaza (another brand name for a similar drug) was made by SingleCare [2]. Both drugs have been shown to reduce triglyceride levels, but Vascepa has been found to be more effective in lowering the risk of cardiovascular events. Lovaza has also been linked to side effects such as upset stomach and fishy aftertaste, which are not typically associated with Vascepa.

Additionally, a study published in the National Library of Medicine [3] compared the efficacy of Vascepa with a placebo. The study found that Vascepa was effective in reducing triglyceride levels and the risk of cardiovascular events in patients with high triglyceride levels.

In conclusion, while there are currently no FDA-approved generic versions of Vascepa available, studies have shown that Vascepa is more effective than Lovaza in reducing the risk of cardiovascular events and has fewer side effects. A study also found that Vascepa was effective in reducing triglyceride levels and the risk of cardiovascular events.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.singlecare.com/blog/vascepa-vs-lovaza/
[3] https://www.ncbi.nlm.nih.gov/books/NBK566011/